Stock · MRK.DE · Healthcare
Germany · Large Cap · Revenue 12 mo. €21.1B
Price as of 11/06/2026
Merck KGaA operates as a science and technology company in Europe, North America, Latin America, Middle East and Africa, and the Asia Pacific.
Merck KGaA operates as a science and technology company in Europe, North America, Latin America, Middle East and Africa, and the Asia Pacific. The Life Science segment offers products, solutions, and services to academic, research and diagnostic labs, biotech, and pharmaceutical companies, as well as the industrial sector; reagents, consumables, devices, instruments, software, and services for research, production, and testing to lab water instruments, microbiology and biomonitoring products, test assays, analytical reagents, and flow cytometry kits and instruments. This segment also provides traditional and novel therapies, such as ration devices, chromatography resins, single-use systems, process chemicals, and excipients for bioprocessing; contract development, manufacturing and testing services, which supports customers from preclinical phases to commercialization. The Healthcare segment discovers, develops, manufactures, and markets prescription drugs and biopharmaceuticals to the therapeutic areas of oncology, rare diseases, neurology and immunology, fertility, cardiovascular, and metabolic and endocrinological disorders. The Electronics segment offers advanced dielectric and metallic materials; photoresist, anti-reflective coating, and material lithography products; clean and selective etch chemistries; materials for chemical-mechanical planarization; high-purity gases for semiconductor manufacturing; and develops and installs delivery equipment for handling of specialty chemicals and gases for semiconductor manufacturing; develops modulating, creating, engineering, and guiding light; and material solutions in liquid crystals, OLED materials, and photoresists. It has in-licensing agreement with Abbisko Therapeutics Co. Ltd., China on drug candidates for the treatment of tenosynovial giant cell tumor; and strategic partnership with Versant Ventures to advance treatments for rare genetic cardiomyopathies. The company was founded in 1668 and is headquartered in Darmstadt, Germany. Merck KGaA operates as a sub
Original text from the data provider
Summary
50.4 of 100
Mean of the six area values. Each area value is the mean of the stock's ranks among the companies in its sector. 50 is the middle of the sector, not a share of companies beaten.
Analysis
What the price requires
If free cash flow stays at €2.3B (2025), it supports €26.1B. The remaining €39.1B of the market value assume it grows 12.8% a year for 10 years and not at all afterwards.
Required FCF growth per year
12.8%
no growth afterwards
Price to operating cash flow 15.3×, within its usual range.
Middle half of 20 quarters: 13.5× to 17.6×, median 16.4×.
Measures only against its own past, not against what the company is worth. Price as of 11/06/2026.
with respect to the priced-in expectation
with respect to the priced-in expectation
Since the last quarter
Q1 → Q2 2026
6 more unchanged: Revenue, 12 mo., Gross margin, EBIT margin, FCF margin, Shares outstanding, Return on equity
Derivation
Each area value is the average of its metrics' ranks within the sector (0 to 100, 50 is the middle). For metrics where lower is better, the rank is mirrored. The overall value is the average of the area values.
Price as of 11/06/2026.
| Metric | Stock | Sector median | Position in sector |
|---|---|---|---|
| Return on equity | 9.12% | 11.52% | Rank 39 |
| Return on capital (Greenblatt) | 28.77% | 32.55% | Rank 43 |
| EBIT margin | 19.26% | 18.31% | Rank 56 |
| FCF margin | 11.13% | 14.12% | Rank 36 |
| Gross margin | 56.35% | 60.99% | Rank 44 |
| Metric | Stock | Sector median | Position in sector |
|---|---|---|---|
| Revenue growth, 1 year | −0.26% | 8.04% | Rank 11 |
| Earnings growth, 3 years per year | −7.78% | 5.44% | Rank 22 |
| Earnings growth, 5 years per year | 5.59% | 7.00% | Rank 43 |
| Sustainable growth (ROE × retained earnings) | 7.51% | 3.66% | Rank 86 |
| Metric | Stock | Sector median | Position in sector |
|---|---|---|---|
| Earnings yield | 4.03% | 2.90% | Rank 69 |
| FCF yield | 3.60% | 3.63% | Rank 49 |
| EV/saleslower is better | 3.52 | 4.03 | Rank 53 |
| EV/EBITlower is better | 18.27 | 21.73 | Rank 64 |
| Metric | Stock | Sector median | Position in sector |
|---|---|---|---|
| Share price, 1 year | 25.25% | 8.66% | Rank 74 |
| Share price, 6 months | 32.30% | 24.27% | Rank 71 |
| Share price, 3 months | 8.68% | 15.42% | Rank 31 |
| Distance from 52-week high | −1.69% | −7.35% | Rank 77 |
| Metric | Stock | Sector median | Position in sector |
|---|---|---|---|
| Accruals (Sloan)lower is better | 5.67% | 0.30% | Rank 16 |
| Change in share countlower is better | 0.00% | 0.00% | Rank 45 |
| Dividend streak in years | 4 | 10 | Rank 46 |
| Price reaction to results, market-adjusted | 0.35% | 0.05% | Rank 52 |
| Metric | Stock | Sector median | Position in sector |
|---|---|---|---|
| Equity ratio | 54.88% | 48.40% | Rank 61 |
| Net debt/EBITDAlower is better | 1.66 | 1.11 | Rank 40 |
| Debt to equitylower is better | 0.42 | 0.48 | Rank 53 |
| Volatility, 1 yearlower is better | 27.71% | 31.42% | Rank 72 |
Ten years in figures
| Year | Revenue, €B | EBIT margin | FCF, €B | Shares | Net debt, €B |
|---|---|---|---|---|---|
| 2016 | 15.0 | 15.8% | 1.7 | 434M | 11.5 |
| 2017 | 14.5 | 13.8% | 1.4 | 435M | 10.1 |
| 2018 | 14.8 | 11.8% | 1.2 | 435M | 6.6 |
| 2019 | 16.2 | 12.4% | 1.8 | 435M | 12.6 |
| 2020 | 17.5 | 18.0% | 1.9 | 435M | 10.9 |
| 2021 | 19.7 | 21.8% | 3.2 | 435M | 9.3 |
| 2022 | 22.2 | 22.5% | 2.5 | 435M | 9.0 |
| 2023 | 21.0 | 19.3% | 1.8 | 435M | 8.0 |
| 2024 | 21.2 | 20.6% | 2.4 | 435M | 8.1 |
| 2025 | 21.1 | 19.3% | 2.3 | 435M | 9.2 |
1 of 7 StockScorer Score rules met · How the score is built
Merck KGaA mainly meets criteria in the Momentum category. Result from 18 strategies checked.
Merck KGaA is rated here with the StockScorer Score strategy, the flagship rule set. It compares return and cash-flow metrics with the median of the company's own sector and checks growth and price trend.
1 of 7 rules met
1 of 11 points
Detail data
Excerpt from 18 strategies checked. The full evaluation is visible after a free sign-up.
With a free account, you can see the match across all strategies checked in one complete overview.
Selected fundamental metrics for Merck KGaA.
| Metric | Stock | Sector |
|---|---|---|
| P/E ratio | 24.8 | 30.0 |
| P/B ratio | 2.3 | 4.8 |
| Return on equity (ROE) | 9.1% | 11.5% |
| Equity ratio | 54.9% | 48.4% |
| Debt-to-equity (D/E) | 0.42 | 0.48 |
| Dividend yield | 1.5% | 1.3% |
How comparable stocks in the same sector score in the StockScorer model.
| Symbol | Company | Rating |
|---|---|---|
| MRK.DE | Merck KGaAthis page | |
| 4502.T | Takeda Pharmaceutical Co. Ltd. | locked |
| GALD.SW | Galderma Group N | locked |
| 600276.SS | Jiangsu Hengrui Medicine Co Ltd | locked |
| TEVA.TA | Teva Pharmaceutical Industries Ltd | locked |
| SUNPHARMA.NS | Sun Pharmaceutical Industries Limited | locked |
Signed up in 30 seconds, free.
Learn more about the metrics in the metrics glossary or all rated stocks in the stock overview.
How StockScorer rates every stock is explained on the methodology page.